GCT has been awarded a new major project by Kangen Pharmaceuticals — a Phase II parallel-group dose-ranging study to evaluate the safety and efficacy of the drug compared to placebo in patients with chronic pancreatitis. Being the experts in the Eastern Europe for 17 years, our team will be responsible for handling the full range of regulatory activities and regional project management in Russia and Ukraine.
In order to enhance the enrollment and to keep up with the Sponsor’s timelines in the US-based study, GCT has conducted feasibility and offered a strategy to facilitate the recruitment of 164 patients.